SLSG Blog
Our blog will keep you informed of all the latest news and developments in the growing CBD industry. Alongside articles from the news, we will also keep you updated about what’s happening at Swiss Life Sciences Group.
Cannabis and Green Economy
16. 11. 2021Related posts: CBD may reduce the adverse effects of anti-seizure drugs in people with epilepsy Italy and it’s referendum on ...Read More
Swiss Life Sciences Group Opens Funding Platform for the CBD Industry
8. 11. 2021Related posts: CBD may reduce the adverse effects of anti-seizure drugs in people with epilepsy Italy and it’s referendum on ...Read More
Swiss Life Sciences Group Launches RawSwiss Lifestyle Brand
13. 9. 2021Swiss Life Sciences Group (SLSG) continues its expansion in the CBD marketplace and is proud to announce the launch of its RawSwiss CBD lifestyle brand. ...Read More
UK Government Vows To Make UK Life Sciences Superpower
29. 8. 2021The Health and Social Care Secretary Matt Hancock has announced a £37 million investment in genomics projects and data-driven initiatives, which could see patients, including those affected by epilepsy, benefit from better research, treatment, and improved clinical decision-making. ...Read More
Swiss Life Sciences Group Develops Cannabis Genetics For Healthcare
23. 8. 2021Swiss Life Sciences Group Plc (SLSG) is pleased to announce its partnership with Switzerland’s leading cannabis and CBDgenetics experts, Bio Zu Farm, who have been developing their own cannabis genetics for more than 25 years. ...Read More
CBD and THC: What’s the Difference?
8. 7. 2021Scientists have identified more than 120 different cannabinoids in the cannabis plant, but the most familiar are THC (delta-9 or delta-8 tetrahydrocannabinol) and CBD (cannabidiol). These two naturally occurring compounds have distinct properties that make them different from one another. ...Read More
Swiss Life Sciences Group Plc Announces Cannabis Technology Investment
10. 5. 2021Swiss Life Sciences Group Plc is a cannabis-sector private equity company based in London. It has been researching and identifying strategic investments in the fast-growing medical cannabis and phytocannabinoid industry since 2019 and is now focused on developing strategic acquisitions and investments in Switzerland. ...Read More
UK’s Largest Seed-to-Consumer CBD Manufacturer to Develop GMP-Certified CBD Facility
18. 4. 2021Swiss Life Sciences Group Plc is setting its sights on becoming one of the next-generation seed-to-consumer companies in the fast-growing medical cannabis and CBD wellness sectors.
...Read More
Swiss Life Sciences Group CBD – Disruption Through Transparency
18. 4. 2021Swiss Life Sciences Group has emerged as one of the largest seed-to-consumer, vertically integrated CBD manufacturers in the European market. Our company aims to provide a transparent and trustworthy network of brands to give consumers peace of mind, in an often unprincipled market. ...Read More